InvestorLens

BDSX — BIODESIX INC

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BDSX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 1 selling last quarter
2
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their BDSX position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investors reported holding BDSX at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About BIODESIX INC (BDSX)

BIODESIX INC (BDSX) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $540,801. Across recent filings, tracked investors recorded 4 new positions, 2 increased, 2 reduced, and 3 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BDSX

55
/100
Mixed Activity
Added / Increased6
Reduced2
Exited3
BearishBullish
Crowded Trade Score™

How many top investors track BDSX

7
/100
Undiscovered
1investor

Only 1 tracked investor report this position.

UndiscoveredCrowded
151015+

BDSX Ownership Composition

How BIODESIX INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
1
tracked investors
Total Reported
$324.8K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(1)
100.0%

Tracked investors currently reporting BDSX

1 tracked investor has since exited this position — listed separately below.

  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    14.4K
    Value
    $324.8K
    % Portfolio
    0.00%

Previously held BDSX

These investors reported BDSX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Ken GriffinCitadel Advisors26K$176.7KDec 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold BDSX?
1 tracked institutional investor disclosed a position in BDSX (BIODESIX INC) in their most recent 13F filing.
Who is the largest institutional holder of BDSX?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in BDSX, valued at $540,801.
Did institutional ownership of BDSX increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 2 increased, 2 reduced, and 3 fully exited BDSX.
Where does this BDSX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.